Diagnosis, monitoring and management of immune-related adverse drug reactions of anti-PD-1 antibody therapy

Cancer Treatment Reviews

Volumn 45, Issue , 2016, Pages 7-18

  Eigentler, Thomas K ^a   Hassel, Jessica C ^b   Berking, Carola ^c   Aberle, Jens ^d   Bachmann, Oliver ^e   Grünwald, Viktor ^e   Kähler, Katharina C ^f   Loquai, Carmen ^g   Reinmuth, Niels ^h   Steins, Martin ⁱ   Zimmer, Lisa ^j   Sendl, Anna ^k   Gutzmer, Ralf ^e  

^a UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

^b UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

^c LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^d UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^e HANNOVER MEDICAL SCHOOL   (Germany)

^f UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

^g JOHANNES GUTENBERG UNIVERSITY   (Germany)

^h Department of Thoracic Oncology ^*  (Germany)

ⁱ UNIVERSITY OF HEIDELBERG   (Germany)

^j UNIVERSITY OF DUISBURG ESSEN   (Germany)

^k BRISTOL MYERS SQUIBB   (United States)

more..

Author keywords

Adverse drug reaction; Immune related adverse events; Immunotherapy; Nivolumab; PD 1; Pembrolizumab

Indexed keywords

ANTIDIARRHEAL AGENT; ANTIHISTAMINIC AGENT; ANTIPRURITIC AGENT; GLUCOCORTICOID; IPILIMUMAB; LEVOTHYROXINE; METHYLPREDNISOLONE; NIVOLUMAB; PEMBROLIZUMAB; PROGRAMMED DEATH 1 RECEPTOR; THIAMAZOLE; UREA; ANTINEOPLASTIC AGENT; IMMUNOSUPPRESSIVE AGENT; MONOCLONAL ANTIBODY; PROGRAMMED DEATH 1 LIGAND 1;

ACUTE KIDNEY FAILURE; ADRENAL INSUFFICIENCY; ADVANCED CANCER; ADVERSE DRUG REACTION; ARTICLE; AUTOIMMUNE HEPATITIS; AUTOIMMUNE THYROIDITIS; BLOOD CELL COUNT; CLINICAL CHEMISTRY; CLINICAL EXAMINATION; CLINICAL TRIAL (TOPIC); COLITIS; DIABETES MELLITUS; DIABETIC KETOACIDOSIS; DIARRHEA; DISEASE SEVERITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG CONTRAINDICATION; DRUG HALF LIFE; DRUG HYPERSENSITIVITY; DRUG SURVEILLANCE PROGRAM; DRUG WITHDRAWAL; EARLY DIAGNOSIS; ELECTROLYTE INTAKE; HORMONE SUBSTITUTION; HUMAN; HYDRATION; HYPERTHYROIDISM; HYPERTRANSAMINASEMIA; HYPOPHYSITIS; HYPOTHYROIDISM; IMMUNE RELATED ADVERSE DRUG REACTION; INFUSION RELATED REACTION; INTERSTITIAL NEPHRITIS; KIDNEY FAILURE; LABORATORY TEST; LIVER DYSFUNCTION; MACULOPAPULAR RASH; MELANOMA; NON SMALL CELL LUNG CANCER; NONHUMAN; PATIENT MONITORING; PHARMACODYNAMICS; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PNEUMONIA; PRURITUS; RASH; RISK BENEFIT ANALYSIS; SEROLOGY; SQUAMOUS CELL CARCINOMA; STEADY STATE; SYMPTOMATOLOGY; TOXIC HEPATITIS; TREATMENT WITHDRAWAL; ANTAGONISTS AND INHIBITORS; DISEASE MANAGEMENT; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; IMMUNOLOGICAL MONITORING; IMMUNOLOGY; NEOPLASMS;

ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTIGENS, CD274; ANTINEOPLASTIC AGENTS; DISEASE MANAGEMENT; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; EARLY DIAGNOSIS; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MONITORING, IMMUNOLOGIC; NEOPLASMS; PROGRAMMED CELL DEATH 1 RECEPTOR;

EID: 84959231890     PISSN: 03057372     EISSN: 15321967     Source Type: Journal    
DOI: 10.1016/j.ctrv.2016.02.003     Document Type: Review

References (53)

1. Postow M.A., Callahan M.K., Wolchok J.D. Immune checkpoint blockade in cancer therapy. J Clin Oncol 2015, 33:1974-1982.
2. McDermott D.F., Drake C.G., Sznol M., Choueiri T.K., Powderly J.D., Smith D.C., et al. Survival, durable response, and long-term safety in patients with previously treated advanced renal cell carcinoma receiving nivolumab. J Clin Oncol 2015, 33:2013-2020.
3. Motzer R.J., Rini B.I., McDermott D.F., Redman B.G., Kuzel T.M., Harrison M.R., et al. Nivolumab for metastatic renal cell carcinoma: results of a randomized phase II trial. J Clin Oncol 2015, 33:1430-1437.
4. Motzer R.J., Escudier B., McDermott D.F., George S., Hammers H.J., Srinivas S., et al. Nivolumab versus everolimus in advanced renal-cell carcinoma. N Engl J Med 2015, 373:1803-1813.
5. Powles T., Eder J.P., Fine G.D., Braiteh F.S., Loriot Y., Cruz C., et al. MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer. Nature 2014, 515:558-562.
6. Ansell S.M., Lesokhin A.M., Borrello I., Halwani A., Scott E.C., Gutierrez M., et al. PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma. N Engl J Med 2015, 372:311-319.
7. Topalian S.L., Sznol M., McDermott D.F., Kluger H.M., Carjaval R.D., Sharfman W.H., et al. Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab. J Clin Oncol 2014, 32:1020-1030.
8. Weber J.S., D'Angelo S.P., Minor D., Hodi F.S., Gutzmer R., Neyns B., et al. Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial. Lancet Oncol 2015, 16:375-384.
9. Robert C., Long G.V., Brady B., Dutriaux C., Maio M., Mortier L., et al. Nivolumab in previously untreated melanoma without BRAF mutation. N Engl J Med 2015, 372:320-330.
10. Robert C., Ribas A., Wolchok J.D., Hodi F.S., Hamid O., Kefford R., et al. Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial. Lancet 2014, 384:1109-1117.
11. Ribas A., Puzanov I., Dummer R., Schadendof D., Hamid O., Robert C., et al. Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial. Lancet Oncol 2015, 16:908-918.
12. Robert C., Schachter J., Long G.V., Arance A., Grob J.J., Mortier L., et al. Pembrolizumab versus ipilimumab in advanced melanoma. N Engl J Med 2015, 372:2521-2532.
13. Gettinger S.N., Horn L., Gandhi L., Spigel D.R., Antonia S.J., Rizvi N.A., et al. Overall survival and long-term safety of nivolumab (anti-programmed death 1 antibody, BMS-936558, ONO-4538) in patients with previously treated advanced non-small-cell lung cancer. J Clin Oncol 2015, 33:2004-2012.
14. Rizvi N.A., Mazières J., Planchard D., Stinchcombe T.E., Dy G.K., Antonia S.J., et al. Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): a phase 2, single-arm trial. Lancet Oncol 2015, 16:257-265.
15. Brahmer J., Reckamp K.L., Baas P., Crino L., Eberhardt W.E., Poddubskaya E., et al. Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer. N Engl J Med 2015, 373:123-135.
16. Borghaei H., Paz-Ares L., Horn L., Spigel D.R., Steins M., Ready N.E., et al. Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer. N Engl J Med 2015, 373:1627-1639.
17. Garon E.B., Rizvi N.A., Hui R., Leighl N., Balmanoukian A.S., Eder J.P., et al. Pembrolizumab for the treatment of non-small-cell lung cancer. N Engl J Med 2015, 372:2018-2028.
18. EMA, European Public Assessment Report Opdivo (EMA/CHMP/76688/2015).
19. EMA, European Public Assessment Report Nivolumab-BMS (EMA/CHMP/392114/2015).
20. EMA, European Public Assessment Report Keytruda (EMA/CHMP/444458/2015).
21. FDA, Drug Approval Package Opdivo (nivolumab) Injection (BLA 125554, 22 Dec 2014).
22. FDA, Drug Approval package Keytruda (pembrolizumab) Powder for Injection (BLA125514, 4 Sep 2014).
23. ICH, ICH E2A, Tripartite Guideline on Clinical Safety Data Management: Definitions and Standards for Expedited Reporting (October 1994).
24. ICH, Introductory Guide MedDRA Version 17.1. (MSSO-DI-6003-17.1.0, September 2014).
25. US, National Cancer Institute, Common terminology criteria for adverse events (CTCAE). Version 4.0; Published: May 28, 2009 (v4.03: June 14, 2010).
26. Guyatt G.H., Oxman A.D., Vist G.E., Kunz R., Falck-Ytter Y., Alonso-Coello P., et al. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ 2008, 336:924-926.
27. Brahmer J.R., Drake C.G., Wollner I., Powderly J.D., Picus J., Sharfman W.H., et al. Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates. J Clin Oncol 2010, 28:3167-3175.
28. Topalian S.L., Hodi F.S., Brahmer J.R., Gettinger S.N., Smith D.C., McDermott D.F., et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med 2012, 366:2443-2454.
29. Patnaik A., Kang S.P., Rasco D., Papadopoulos K.P., Elassaiss-Schaap J., Beeram M., et al. Phase I study of pembrolizumab (MK-3475; Anti-PD-1 monoclonal antibody) in patients with advanced solid tumors. Clin Cancer Res 2015, 21:4286-4293.
30. Weber J.S., Yang C.Y., Atkins M.B., Disis M.L. Toxicities of immunotherapy for the practitioner. J Clin Oncol 2015, 33:2092-2099.
31. Beck K.E., Blansfield J.A., Tran K.Q., Feldman A.L., Hughes M.S., Royal R.E., et al. Enterocolitis in patients with cancer after antibody blockade of cytotoxic T-lymphocyte-associated antigen 4. J Clin Oncol 2006, 24:2283-2289.
32. Kaehler K.C., Piel S., Livingstone E., Schilling B., Hauschild A., Schadendorf D. Update on immunologic therapy with anti-CTLA-4 antibodies in melanoma: identification of clinical and biological response patterns, immune-related adverse events, and their management. Semin Oncol 2010, 37:485-498.
33. Weber J.S., Kähler K.C., Hauschild A. Management of immune-related adverse events and kinetics of response with ipilimumab. J Clin Oncol 2012, 30:2691-2697.
34. Pagès C., Gornet J.M., Monsel G., Allez M., Bertheau P., Bagot M., et al. Ipilimumab-induced acute severe colitis treated by infliximab. Melanoma Res 2013, 23:227-230.
35. Merrill S.P., Reynolds P., Kalra A., Biehl J., Vandivier R.W., Mueller S.W. Early administration of infliximab for severe ipilimumab-related diarrhea in a critically ill patient. Ann Pharmacother 2014, 48:806-810.
36. Weber J.S., Kudchadkar R.R., Yu B., Gallenstein D., Horak C.E., Inzunza H.D., et al. Safety, efficacy, and biomarkers of nivolumab with vaccine in ipilimumab-refractory or -naive melanoma. J Clin Oncol 2013, 31:4311-4318.
37. Weber J., Thompson J.A., Hamid O., Minor D., Amin A., Ron I., et al. A randomized, double-blind, placebo-controlled, phase II study comparing the tolerability and efficacy of ipilimumab administered with or without prophylactic budesonide in patients with unresectable stage III or IV melanoma. Clin Cancer Res 2009, 15:5591-5598.
38. Lammert A., Schneider H.J., Bergmann T., Benck U., Krämer B.K., Gärtner R., et al. Hypophysitis caused by ipilimumab in cancer patients: hormone replacement or immunosuppressive therapy. Exp Clin Endocrinol Diabetes 2013, 121:581-587.
39. Naidoo J., Page D.B., Li B.T., Connell L.C., Schindler K., Lacouture M.E., et al. Toxicities of the anti-PD-1 and anti-PD-L1 immune checkpoint antibodies. Ann Oncol 2015, 26:2375-2391.
40. Uslu U., Agaimy A., Hundorfean G., Harrer T., Schuler G., Heinzerling L. Autoimmune colitis and subsequent CMV-induced hepatitis after treatment with ipilimumab. J Immunother 2015, 38:212-215.
41. Weber J.S., Antonia J.S., Topalian S., Schadendorf D., Larkin J., Sznol M., et al. Safety profile of nivolumab (NIVO) in patients (pts) with advanced melanoma (MEL): a pooled analysis. J Clin Oncol 2015, 33. (suppl; abstr 9018).
42. Feng Y., Roy A., Masson E., Chen T.T., Humphrey R., Weber J.S. Exposure-response relationships of the efficacy and safety of ipilimumab in patients with advanced melanoma. Clin Cancer Res 2013, 19:3977-3986.
43. Kaehler K.C., Hauschild A. Treatment and side effect management of CTLA-4 antibody therapy in metastatic melanoma. J Dtsch Dermatol Ges 2011, 9:277-286.
44. Robert C., Schadendorf D., Messina M., Hodi F.S., O'Day S. MDX010-20 investigators. Efficacy and safety of retreatment with ipilimumab in patients with pretreated advanced melanoma who progressed after initially achieving disease control. Clin Cancer Res 2013, 19:2232-2239.
45. Horvat T.Z., Adel N.G., Dang T.O., Momtaz P., Postow M.A., Callahan M.K., et al. Immune-related adverse events, need for systemic immunosuppression, and effects on survival and time to treatment failure in patients with melanoma treated with ipilimumab at memorial sloan kettering cancer center. J Clin Oncol 2015, 33:3193-3198.
46. Dienstmann R., Braña I., Rodon J., Tabernero J. Toxicity as a biomarker of efficacy of molecular targeted therapies: focus on EGFR and VEGF inhibiting anticancer drugs. Oncologist 2011, 16:1729-1740.
47. Liu S., Kurzrock R. Toxicity of targeted therapy: implications for response and impact of genetic polymorphisms. Cancer Treat Rev 2014, 40:883-891.
48. Freeman-Keller M., Kim Y., Cronin H., Richards A., Gibney G., Weber J. Nivolumab in resected and unresectable metastatic melanoma: characteristics of immune-related adverse events and association with outcomes. Clin Cancer Res 2016, 22:886-894.
49. Sanlorenzo M., Vujic I., Daud A., Algazi A., Gubens M., Luna S.A., et al. Pembrolizumab cutaneous adverse events and their association with disease progression. JAMA Dermatol 2015, 151:1206-1212.
50. Hua C., Boussemart L., Mateus C., et al. Association of vitiligo with tumor response in patients with metastatic melanoma treated with pembrolizumab. JAMA Dermatol 2016, 152:45-51.
51. Gangadhar T.C., Vonderheide R.C. Mitigating the toxic effects of anticancer immunotherapy. Nat Rev Clin Oncol 2014, 11:91-99.
52. Postow M.A., Chesney J., Pavlick A.C., Robert C., Grossmann K., McDermott D., et al. Nivolumab and ipilimumab versus ipilimumab in untreated melanoma. N Engl J Med 2015, 372:2006-2017.
53. Larkin J., Chiarion-Sileni V., Gonzalez R., Grob J.J., Cowey C.L., Lao C.D., et al. Combined nivolumab and ipilimumab or monotherapy in untreated melanoma. N Engl J Med 2015, 373:23-34.